May 24, 2024
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
May 22, 2024
BioLineRx to Report First Quarter 2024 Results on May 28, 2024
May 17, 2024
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
May 06, 2024
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
Apr 17, 2024
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
May 26, 2020
BioLineRx Announces $9.0 Million Registered Direct Offering
Mar 06, 2020
BioLineRx to Report Annual 2019 Results on March 12, 2020
Jan 14, 2020
BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe
Jan 08, 2020
BioLineRx to Present at the 2020 Biotech Showcase
Nov 26, 2019
BioLineRx to Host Investor and Analyst Breakfast Meeting on December 5, 2019 in New York
Nov 06, 2019
BioLineRx to Report Third Quarter 2019 Results on November 11, 2019
Oct 31, 2019
BioLineRx to Present Two Posters at the Society for Immunotherapy of Cancer (SITC) 2019
Oct 29, 2019
BioLineRx to Deliver Oral Presentation at ESMO Immuno-Oncology Congress 2019
Sep 25, 2019
BioLineRx Announces Dosing of First Patient in Part 2 of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
Sep 03, 2019
BioLineRx Successfully Completes Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
Jul 30, 2019
BioLineRx to Report Second Quarter 2019 Results on August 6, 2019
Jun 28, 2019
BioLineRx Announces Change in Ratio of American Depositary Shares to Ordinary Shares
Jun 13, 2019
BioLineRx to Present at the JMP Securities 2019 Life Sciences Conference
May 13, 2019
Frost & Sullivan Publishes Annual Update on BioLineRx
May 07, 2019
BioLineRx to Report First Quarter 2019 Results on May 14, 2019